Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of Friday, August 28, 2026.
Forward PE Ratio (N/A) = Close Price ($44.76) / Consensus Forward EPS ($4.18)
FORWARD PE RATIO
N/A
Sanofi
Market Cap
$107.48B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Sanofi (SNY) | $107.48B | N/A |
| McKesson Corporation (MCK)vs › | $104.87B | 22.83 |
| GSK plc (GSK)vs › | $100.54B | 14.03 |
| Medtronic plc (MDT)vs › | $116.60B | 16.30 |
| CVS Health Corp. (CVS)vs › | $119.16B | 11.65 |
| HCA Healthcare, Inc. (HCA)vs › | $90.56B | 14.21 |
| Stryker Corporation (SYK)vs › | $125.43B | 21.44 |
| Elevance Health Inc. (ELV)vs › | $86.04B | 14.70 |
| Intuitive Surgical, Inc. (ISRG)vs › | $131.04B | 33.99 |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $81.51B | 14.89 |
Trailing P/E
80.5
reported TTM EPS
Forward P/E
N/A
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $4.18 implies +646.4% EPS growth vs the reported trailing $0.56.
At today's $44.76 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $4.18 | $4.03 – $4.31 | 6 | 10.7x |
| 2027-12-31 | $4.47 | $3.97 – $4.74 | 6 | 10.0x |
| 2028-12-31 | $4.90 | $4.60 – $5.18 | 3 | 9.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
